Clinical Trials Logo

Filter by:
NCT ID: NCT05842993 Recruiting - Type 2 Diabetes Clinical Trials

Study of Hydrogen Inhalation Compared With Placebo in Type 2 Diabetes Patients

Start date: May 1, 2023
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of hydrogen inhalation in type 2 diabetes patients.

NCT ID: NCT05842980 Recruiting - Sepsis Clinical Trials

BIomarkers to Predict the Outcomes of Sepsis

BIPROS
Start date: June 1, 2020
Phase:
Study type: Observational

Sepsis is an organ dysfunction syndrome caused by the host's immune response to infection, and is one of the common critical illnesses. However, sepsis remains the main threat to global health. Due to the high heterogeneity, the diagnosis of sepsis is difficult, and it is particularly important to find biomarkers that can predict changes in the patient's condition and prognosis. The purpose of this study is to collect patient blood samples for testing and identify biomarkers related to the prognosis of sepsis.

NCT ID: NCT05842785 Recruiting - Clinical trials for Has a Pathologically Documented Unresectable Locally Advanced or Metastatic Solid Tumor or Lymphoma

TSN222 in Subjects With Advanced Solid Tumors or Lymphomas

Start date: July 26, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

The study is a first-in-human [FIH], open-label phase 1/2 study of TSN222 in subjects with advanced solid tumors or lymphomas. This study is comprised of a Phase 1 dose escalation and Phase 2 dose expansion component.

NCT ID: NCT05842707 Recruiting - Clinical trials for Refractory or Relapsed B-cell Non-Hodgkin Lymphoma

Study of Cord Blood-derived CAR NK Cells Targeting CD19/CD70 in Refractory/Relapsed B-cell Non-Hodgkin Lymphoma

Start date: January 18, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

To find the highest tolerable dose of dualCAR-NK19/70 (a type of cell therapy) that can be given to patients who have B-cell lymphoma that is relapsed or refractory.

NCT ID: NCT05842317 Recruiting - Clinical trials for Hepatocellular Carcinoma

Lenvatinib Plus Tislelizumab With or Without TACE in First-line Treatment of Unresectable HCC

Start date: September 1, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

To explore the effects of lenvatinib in combination with tislelizumab with or without TACE in patients with hepatocellular carcinoma on survival, disease progression, and medication safety.

NCT ID: NCT05842304 Recruiting - Stroke, Ischemic Clinical Trials

Individualized Precision rTMS for Language Recovery in Patients After Ischemic Stroke: a Multi-center RCT

Start date: June 5, 2023
Phase: N/A
Study type: Interventional

The current multi-center study aims to evaluate the efficacy and safety of pBFS-guided rTMS Neuromodulation Treatment for the rehabilitation of language functions in ischemic stroke aphasic patients.

NCT ID: NCT05842291 Recruiting - Clinical trials for Treatment-Resistant Depression

pBFS Guided High-dose rTMS Therapy for Treatment-Resistant Depression

Start date: June 19, 2023
Phase: N/A
Study type: Interventional

We aim to evaluate the safety and efficacy of pBFS-guided high-dose rTMS therapy with short inter-session interval for patients with treatment-resistant depression

NCT ID: NCT05842278 Recruiting - Clinical trials for Major Depressive Disorder

The Dosage Effect of pBFS Guided rTMS Treatment for MDD

Start date: July 7, 2023
Phase: N/A
Study type: Interventional

The investigators aim to find the optimal dosage of the pBFS-guided rTMS treatment for patients with moderate to severe depression.

NCT ID: NCT05842187 Recruiting - Pancreatic Cancer Clinical Trials

In Vitro Organoid Drug Sensitivity-Guided Treatment for Metastatic Pancreatic and Gastric Cancer

ODYSSEY
Start date: March 3, 2023
Phase: N/A
Study type: Interventional

The goal of this study is to evaluate the consistency between in vitro tumor organoid drug sensitivity and the therapeutic efficacy of in vivo drug treatment. Participants are required to provide one of fresh tumor tissues (including ascites, pleural effusion, biopsy tissues, palliative surgery specimens, etc.) for the purpose of culturing tumor organoids.

NCT ID: NCT05841992 Recruiting - Prostate Cancer Clinical Trials

Al18F-PSMA-617 and 68Ga-PSMA-617 PET/CT Imaging in the Same Group of Prostate Cancer Patients

Start date: July 1, 2021
Phase: Phase 2/Phase 3
Study type: Interventional

18F-labeled prostate-specific membrane antigen (PSMA) ligand-positron emission tomography (PET) offers advantages over 68Ga-labeled PSMA ligands. Al18F-PSMA-617 is a novel 18F-PSMA compound used for prostate cancer (PCa) imaging. This pilot study was prospectively designed to compare the lesion detectability of Al18F-PSMA-617 and related 68Ga-PSMA-617 PET/CT in patients with PCa